SOCS1 and diffuse large B-cell lymphoma: For example, diffuse large B-cell lymphoma with SOCS1 mutation–which can be identified through NGS–has a better 5-year overall survival after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone as compared to other molecular subtypes (11).